Redistribution of CD95 into the lipid rafts to treat cancer cells?

Recent Patents on Anti-Cancer Drug Discovery

Volumn 5, Issue 1, 2010, Pages 22-28

  Segui, Bruno ^a,b,c   Legembre, Patrick ^d,e,f  

^a INSERM   (France)

^b IFR 31   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d CNRS Bordeaux Segalen University   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f IFR 66   (France)

Author keywords

Apoptosis; CD95; Ceramide; Chemoresistance; Cisplatin; Lipid rafts; Sphingomyelinase; Tumor

Indexed keywords

BBR 3610; CERAMIDE; CISPLATIN; CISPLATIN DERIVATIVE; EDELFOSINE; FAS ANTIGEN; OXALIPLATIN; PHOSPHOLIPID DERIVATIVE; SPHINGOMYELIN PHOSPHODIESTERASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL MEMBRANE FLUIDITY; CELL PROLIFERATION; CELL STRESS; DNA ADDUCT; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; LIPID RAFT; NONHUMAN; PATENT; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SOLID TUMOR; BIOLOGICAL MODEL; CELL DEATH; CELL MEMBRANE; DRUG EFFECT; METABOLISM; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; CELL DEATH; CERAMIDES; CISPLATIN; HUMANS; MEMBRANE MICRODOMAINS; MODELS, BIOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 77649262828     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489210789702190     Document Type: Article

References (93)

1. McWhinney SR, Goldberg RM, McLeod HL. Platinum neuro-toxicity pharmacogenetics. Mol Cancer Ther 2009; 8: 10-16.
2. Muggia F. Platinum compounds 30 years after the introduction ofcisplatin: Implications for the treatment of ovarian cancer. GynecolOncol 2009; 112: 275-281.
3. Wanebo, J.: US20080033039 (2008).
4. Zhu C, Raber J, Eriksson LA. Hydrolysis process of the secondgeneration platinum-based anticancer drug cis-amminedichloro-cyclohexylamineplatinum(II). J Phys Chem B 2005; 109: 12195-12205.
5. Borst P, Rottenberg S, Jonkers J. How do real tumors becomeresistant to cisplatin? Cell Cycle 2008; 7: 1353-1359.
6. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as adifferential modulator of chemotherapy-induced apoptosis. CancerRes 2003; 63: 6221-6228.
7. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levelsas an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004; 13: 2443-2449.
8. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of theFanconi anemia-BRCA pathway in cisplatin-sensitive ovariantumors. Nat Med 2003; 9: 568-574.
9. Dimanche-Boitrel MT, Meurette O, Rebillard A, Lacour S. Role ofearly plasma membrane events in chemotherapy-induced cell death. Drug Resist Updat 2005; 8: 5-14.
10. Rebillard A, Lagadic-Gossmann D, Dimanche-Boitrel MT.Cisplatin cytotoxicity: DNA and plasma membrane targets. CurrMed Chem 2008; 15: 2656-2663.
11. Lacour S, Hammann A, Grazide S, et al. Cisplatin-induced CD95redistribution into membrane lipid rafts of HT29 human coloncancer cells. Cancer Res 2004; 64: 3593-3598.
12. Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT. Fasligand-independent, FADD-mediated activation of the Fas deathpathway by anticancer drugs. J Biol Chem 1999; 274: 7987-7992.
13. Rebillard A, Tekpli X, Meurette O, et al. Cisplatin-inducedapoptosis involves membrane fluidification via inhibition of NHE1in human colon cancer cells. Cancer Res 2007; 67: 7865-7874.
14. Muppidi JR, Siegel RM. Ligand-independent redistribution of Fas(CD95) into lipid rafts mediates clonotypic T cell death. NatImmunol 2004; 5: 182-189.
15. Papoff G, Hausler P, Eramo A, et al. Identification and charac-terization of a ligand-independent oligomerization domain in theextracellular region of the CD95 death receptor. J Biol Chem 1999;274: 38241-38250.
16. Siegel RM, Frederiksen JK, Zacharias DA, et al. Fas preassociationrequired for apoptosis signaling and dominant inhibition bypathogenic mutations. Science 2000; 288: 2354-2357.
17. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interferingFas gene mutations impair apoptosis in a human autoimmunelymphoproliferative syndrome. Cell 1995; 81: 935-946.
18. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fasassociated with human lymphoproliferative syndrome andautoimmunity. Science 1995; 268: 1347-1349.
19. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. Fas genemutations in the Canale-Smith syndrome, an inherited lympho-proliferative disorder associated with autoimmunity. N Engl J Med 1996; 335: 1643-1649.
20. Straus SE, Jaffe ES, Puck JM, et al. The development oflymphomas in families with autoimmune lymphoproliferativesyndrome with germline Fas mutations and defective lymphocyteapoptosis. Blood 2001; 98: 194-200.
21. Scott FL, Stec B, Pop C, et al. The Fas-FADD death domaincomplex structure unravels signalling by receptor clustering. Nature 2008; 457(7232): 1019-1022.
22. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvementof MACH, a novel MORT1/FADD-interacting protease, inFas/APO-1- and TNF receptor-induced cell death. Cell 1996; 85:803-815.
23. Chinnaiyan AM, Tepper CG, Seldin MF, et al. FADD/MORT1 is acommon mediator of CD95 (Fas/APO-1) and tumor necrosis factorreceptor-induced apoptosis. J Biol Chem 1996; 271: 4961-4965.
24. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995; 14: 5579-5588.
25. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptorsignals by cellular FLIP. Nature 1997; 388: 190-195.
26. Inohara N, Koseki T, Hu Y, Chen S, Nunez G. CLARP, a deatheffector domain-containing protein interacts with caspase-8 andregulates apoptosis. Proc Natl Acad Sci USA 1997; 94: 10717-10722.
27. Beneteau M, Daburon S, Moreau JF, Taupin JL, Legembre P.Dominant-negative Fas mutation is reversed by down-expression ofc-FLIP. Cancer Res 2007; 67: 108-115.
28. Legembre P, Barnhart BC, Peter ME. The relevance of NF-kappaBfor CD95 signaling in tumor cells. Cell Cycle 2004; 3: 1235-1239.
29. Mariani SM, Matiba B, Baumler C, Krammer PH. Regulation ofcell surface APO-1/Fas (CD95) ligand expression by metallo-proteases. Eur J Immunol 1995; 25: 2303-2307.
30. Schneider P, Holler N, Bodmer JL, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated withdownregulation of its proapoptotic activity and loss of livertoxicity. J Exp Med 1998; 187: 1205-1213.
31. Schulte M, Reiss K, Lettau M, et al. ADAM10 regulates FasL cellsurface expression and modulates FasL-induced cytotoxicity andactivation-induced cell death. Cell Death Differ 2007; 14: 1040-1049.
32. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fasligand by shedding. Nat Med 1998; 4: 31-36.
33. Krueger A, Fas SC, Baumann S, Krammer PH. The role of CD95in the regulation of peripheral T-cell apoptosis. Immunol Rev 2003;193: 58-69.
34. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning andexpression of the Fas ligand, a novel member of the tumor necrosisfactor family. Cell 1993; 75: 1169-1178.
35. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA. Fas ligand (CD95ligand) controls angiogenesis beneath the retina. Nat Med 1999; 5:292-297.
36. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fasligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-1192.
37. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995;377: 630-632.
38. French LE, Hahne M, Viard I, et al. Fas and Fas ligand in embryosand adult mice: Ligand expression in several immune-privilegedtissues and coexpression in adult tissues characterized by apoptoticcell turnover. J Cell Biol 1996; 133: 335-343.
39. Stuart PM, Griffith TS, Usui N, et al. CD95 ligand (FasL)-inducedapoptosis is necessary for corneal allograft survival. J Clin Invest 1997; 99: 396-402.
40. Beneteau M, Pizon M, Chaigne-Delalande B, et al. Localization of Fas/CD95 into the lipid rafts on down-modulation of the phos-phatidylinositol 3-kinase signaling pathway. Mol Cancer Res 2008;6: 604-613.
41. Delmas D, Rebe C, Lacour S, et al. Resveratrol-induced apoptosisis associated with Fas redistribution in the rafts and the formationof a death-inducing signaling complex in colon cancer cells. J BiolChem 2003; 278: 41482-41490.
42. Gajate C, Mollinedo F. The antitumor ether lipid ET-18-OCH(3)induces apoptosis through translocation and capping of Fas/CD95into membrane rafts in human leukemic cells. Blood 2001; 98:3860-3863.
43. Stel AJ, Ten Cate B, Jacobs S, et al. Fas receptor clustering andinvolvement of the death receptor pathway in rituximab-mediatedapoptosis with concomitant sensitization of lymphoma B cells tofas-induced apoptosis. J Immunol 2007; 178: 2287-2295.
44. Brown DA, Rose JK. Sorting of GPI-anchored proteins toglycolipid-enriched membrane subdomains during transport to theapical cell surface. Cell 1992; 68: 533-544.
45. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387: 569-572.
46. Parton RG, Richards AA. Lipid rafts and caveolae as portals forendocytosis: New insights and common mechanisms. Traffic 2003;4: 724-738.
47. Cheng PC, Dykstra ML, Mitchell RN, Pierce SK. A role for lipidrafts in B cell antigen receptor signaling and antigen targeting. JExp Med 1999; 190: 1549-1560.
48. Montixi C, Langlet C, Bernard AM, et al. Engagement of T cellreceptor triggers its recruitment to low-density detergent-insolublemembrane domains. EMBO J 1998; 17: 5334-5348.
49. Xavier R, Brennan T, Li Q, McCormack C, Seed B. Membranecompartmentation is required for efficient T cell activation. Immunity 1998; 8: 723-732.
50. Legler DF, Micheau O, Doucey MA, Tschopp J, Bron C. Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation. Immunity 2003; 18: 655-664.
51. Eramo A, Sargiacomo M, Ricci-Vitiani L, et al. CD95 death-inducing signaling complex formation and internalization occur inlipid rafts of type I and type II cells. Eur J Immunol 2004; 34:1930-1940.
52. Hueber AO, Bernard AM, Herincs Z, Couzinet A, He HT. Anessential role for membrane rafts in the initiation of Fas/CD95-triggered cell death in mouse thymocytes. EMBO Rep 2002; 3:190-196.
53. Legembre P, Daburon S, Moreau P, et al. Amplification of Fas-mediated apoptosis in type II cells via microdomain recruitment. Mol Cell Biol 2005; 25: 6811-6820.
54. Miyaji M, Jin ZX, Yamaoka S, et al. Role of membranesphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J Exp Med 2005; 202: 249-259.
55. Scheel-Toellner D, Wang K, Singh R, et al. The death-inducingsignalling complex is recruited to lipid rafts in Fas-inducedapoptosis. Biochem Biophys Res Commun 2002; 297: 876-879.
56. Brenner B, Ferlinz K, Grassme H, et al. Fas/CD95/Apo-I activatesthe acidic sphingomyelinase via caspases. Cell Death Differ 1998;5: 29-37.
57. De Maria R, Rippo MR, Schuchman EH, Testi R. Acidicsphingomyelinase (ASM) is necessary for fas-induced GD3ganglioside accumulation and efficient apoptosis of lymphoid cells. J Exp Med 1998; 187: 897-902.
58. Cremesti A, Paris F, Grassme H, et al. Ceramide enables fas to capand kill. J Biol Chem 2001; 276: 23954-23961.
59. Paris F, Grassme H, Cremesti A, et al. Natural ceramide reversesFas resistance of acid sphingomyelinase(-/-) hepatocytes. J BiolChem 2001; 276: 8297-8305.
60. Wagenknecht B, Roth W, Gulbins E, Wolburg H, Weller M. C2-ceramide signaling in glioma cells: Synergistic enhancement ofCD95-mediated, caspase-dependent apoptosis. Cell Death Differ 2001; 8: 595-602.
61. Cifone MG, Roncaioli P, De Maria R, et al. Multiple pathwaysoriginate at the Fas/APO-1 (CD95) receptor: Sequential invol-vement of phosphatidylcholine-specific phospholipase C and acidicsphingomyelinase in the propagation of the apoptotic signal. EMBO J 1995; 14: 5859-5868.
62. Segui B, Andrieu-Abadie N, Jaffrezou JP, Benoist H, Levade T. Sphingolipids as modulators of cancer cell death: Potentialtherapeutic targets. Biochim Biophys Acta 2006; 1758: 2104-2120.
63. Kirschnek S, Paris F, Weller M, et al. CD95-mediated apoptosis invivo involves acid sphingomyelinase. J Biol Chem 2000; 275:27316-27323.
64. Lin T, Genestier L, Pinkoski MJ, et al. Role of acidic sphingo-myelinase in Fas/CD95-mediated cell death. J Biol Chem 2000;275: 8657-8663.
65. Bezombes C, Segui B, Cuvillier O, et al. Lysosomal sphin-gomyelinase is not solicited for apoptosis signaling. FASEB J 2001; 15: 297-299.
66. Cock JG, Tepper AD, de Vries E, van Blitterswijk WJ, Borst J. CD95 (Fas/APO-1) induces ceramide formation and apoptosis inthe absence of a functional acid sphingomyelinase. J Biol Chem 1998; 273: 7560-7565.
67. Sabourdy F, Kedjouar B, Sorli SC, et al. Functions of sphingolipidmetabolism in mammals--lessons from genetic defects. BiochimBiophys Acta 2008; 1781: 145-183.
68. Nix M, Stoffel W. Perturbation of membrane microdomainsreduces mitogenic signaling and increases susceptibility toapoptosis after T cell receptor stimulation. Cell Death Differ 2000;7: 413-424.
69. Grassme H, Jekle A, Riehle A, et al. CD95 signaling via ceramide-rich membrane rafts. J Biol Chem 2001; 276: 20589-20596.
70. Cifone MG, De Maria R, Roncaioli P, et al. Apoptotic signalingthrough CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J Exp Med 1994; 180: 1547-1552.
71. De Maria R, Lenti L, Malisan F, et al. Requirement for GD3ganglioside in CD95- and ceramide-induced apoptosis. Science 1997; 277: 1652-1655.
72. Cuvillier O, Edsall L, Spiegel S. Involvement of sphingosine inmitochondria-dependent Fas-induced apoptosis of type II Jurkat Tcells. J Biol Chem 2000; 275: 15691-15700.
73. Grassme H, Cremesti A, Kolesnick R, Gulbins E. Ceramide-mediated clustering is required for CD95-DISC formation. Oncogene 2003; 22: 5457-5470.
74. Huitema K, van den Dikkenberg J, Brouwers JF, Holthuis JC. Identification of a family of animal sphingomyelin synthases. EMBO J 2004; 23: 33-44.
75. Yamaoka S, Miyaji M, Kitano T, Umehara H, Okazaki T. Expression cloning of a human cDNA restoring sphingomyelinsynthesis and cell growth in sphingomyelin synthase-defectivelymphoid cells. J Biol Chem 2004; 279: 18688-18693.
76. Grunicke H, Hofmann J. Cytotoxic and cytostatic effects ofantitumor agents induced at the plasma membrane level. PharmacolTher 1992; 55: 1-30.
77. Aggarwal SK, Niroomand-Rad I. Effect of cisplatin on the plasmamembrane phosphatase activities in ascites sarcoma-180 cells: Acytochemical study. J Histochem Cytochem 1983; 31: 307-317.
78. Nourissat P, Travert M, Chevanne M, et al. Ethanol inducesoxidative stress in primary rat hepatocytes through the earlyinvolvement of lipid raft clustering. Hepatology 2008; 47: 59-70.
79. Salinas M, Lopez-Valdaliso R, Martin D, Alvarez A, Cuadrado A. Inhibition of PKB/Akt1 by C2-ceramide involves activation ofceramide-activated protein phosphatase in PC12 cells. Mol CellNeurosci 2000; 15: 156-169.
80. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidy-linositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 2003; 14: 167-173.
81. Storme GA, Berdel WE, van Blitterswijk WJ, Bruyneel EA, DeBruyne GK, Mareel MM. Antiinvasive effect of racemic 1-O-octadecyl-2-O-methylglycero-3-phosphocholine on MO4 mousefibrosarcoma cells in vitro. Cancer Res 1985; 45: 351-357.
82. Gajate C, Del Canto-Janez E, Acuna AU, et al. Intracellulartriggering of Fas aggregation and recruitment of apoptoticmolecules into Fas-enriched rafts in selective tumor cell apoptosis. J Exp Med 2004; 200: 353-365.
83. Mitchell C, Kabolizadeh P, Ryan J, et al. Low-dose BBR3610toxicity in colon cancer cells is p53-independent and enhanced byinhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling. Mol Pharmacol 2007; 72:704-714.
84. van Blitterswijk WJ, van der Luit AH, Veldman RJ, Verheij M, Borst J. Ceramide: Second messenger or modulator of membranestructure and dynamics? Biochem J 2003; 369: 199-211.
85. Algeciras-Schimnich A, Pietras EM, Barnhart BC, et al. TwoCD95 tumor classes with different sensitivities to antitumor drugs. Proc Natl Acad Sci USA 2003; 100: 11445-11450.
86. Chatterjee, S.B.: US7230094 (2007).
87. Modrak, D.: US6541462 (2003).
88. Wanebo, J., Mehta, S.: US7015251 (2006).
89. Kolesnick, R.: US6274309 (2001).
90. Kolesnick, R., Schuchman, E. H.: US6790627 (2004).
91. Galeotti T, Borrello S, Minotti G, Masotti L. Membrane alterationsin cancer cells: The role of oxy radicals. Ann N Y Acad Sci 1986;488: 468-480.
92. Gehrmann M, Liebisch G, Schmitz G, et al. Tumor-specific Hsp 70 plasma membrane localization is enabled by the glycosphingolipid Gb3. PLoS One 2008; 3: e1925.
93. Gajate C, Mollinedo F. Edelfosine and perifosine induce selectiveapoptosis in multiple myeloma by recruitment of death receptorsand downstream signaling molecules into lipid rafts. Blood 2007;109: 711-719.